Restarting Dayvigo (Lemborexant) After Acute Illness: What Women Need to Know

Why You Paused Lemborexant During Your Illness, and What Changed in Your Body

When an acute illness hits, stopping a sleep medication is often the right call. Fever, dehydration, altered liver blood flow, and the drugs prescribed to treat your infection can all change how lemborexant is metabolized, raising the risk of next-morning sedation or dizziness.

Lemborexant is primarily cleared by CYP3A4, the same enzyme pathway used by many antibiotic and antiviral medications. Illness itself also temporarily reduces hepatic blood flow, which can meaningfully slow first-pass metabolism. That means the same 10 mg tablet that felt perfectly calibrated before your infection may behave more like a higher dose while you are sick.

What "Acute Illness" Does to Lemborexant Pharmacokinetics

The FDA-approved label for lemborexant notes that moderate CYP3A4 inhibitors increase lemborexant exposure by approximately 2-fold. Common illness-era medications that trigger this interaction include:

• Clarithromycin (Z-pack alternative, often prescribed for respiratory infections)
• Fluconazole (frequently used for yeast infections that follow antibiotic courses)
• Certain antivirals including ritonavir-boosted HIV regimens or nirmatrelvir-ritonavir (Paxlovid) for COVID-19

Strong CYP3A4 inhibitors are listed as contraindicated with lemborexant in the prescribing information. Moderate inhibitors require a dose reduction to 5 mg if co-administration is unavoidable. Many clinicians simply advise a hold rather than a reduced dose during short illness courses, which is a reasonable and common practice.

Fever, Dehydration, and Central Nervous System Sensitivity

Fever increases central nervous system (CNS) sensitivity to sedating agents. Dehydration reduces plasma volume, concentrating any drug that remains in circulation. These physiological shifts are not unique to lemborexant, but they are worth naming because many women restart their sleep medication as soon as they begin feeling better, before those parameters have fully normalized.

Waiting until you have been afebrile for at least 24 hours and have resumed near-normal fluid and food intake is not just caution for caution's sake. It reflects real pharmacokinetic reality: your liver's ability to clear lemborexant depends on adequate hepatic blood flow, which correlates with hydration and hemodynamic stability.

The Step-by-Step Restart Protocol

There is no single universal protocol for restarting lemborexant after illness published in a randomized trial, and this is an area where women's data specifically is thin. What follows represents a clinician-derived approach grounded in lemborexant's known pharmacokinetics and the prescribing information, applied to real-world illness scenarios.

Step 1: Confirm Illness Medications Are Cleared

Before you swallow your first post-illness lemborexant tablet, check whether you are still on any medication that inhibits CYP3A4. Use this simplified guide:

| Illness Medication | CYP3A4 Effect | Restart Lemborexant? | |---|---|---| | Amoxicillin, cephalexin | Minimal | Yes, usual dose | | Azithromycin | Mild-to-moderate inhibition | Wait 48 hours after last dose | | Clarithromycin | Moderate inhibitor | Wait 3-5 days after last dose | | Fluconazole (single 150 mg dose) | Moderate, prolonged effect | Wait 5-7 days | | Nirmatrelvir-ritonavir (Paxlovid) | Strong inhibitor via ritonavir | Wait 3-5 days after last dose; confirm with prescriber | | Dextromethorphan-containing cough syrups | Negligible CYP3A4 effect | No adjustment needed | | Ibuprofen, acetaminophen | No CYP3A4 effect | No adjustment needed |

These windows are conservative estimates based on half-life elimination data for the inhibiting drugs. Your pharmacist can verify the specific washout period for anything not listed here.

Step 2: Start at the Lower Dose for the First 3 Nights

Even if you were stable and doing well on 10 mg before your illness, restarting at 5 mg for the first three nights is a reasonable bridge strategy. The SUNRISE-1 trial demonstrated that lemborexant 5 mg produced statistically significant improvements over placebo in sleep onset and wake after sleep onset, so you are not sacrificing efficacy with this approach.

After three nights at 5 mg without residual morning sedation, you can return to 10 mg if that was your established dose.

Step 3: Do Not Take a Higher Dose to Compensate for Missed Nights

A common error after any treatment interruption is the instinct to "catch up." With lemborexant, there is no dose-stacking benefit and a real risk of next-morning impairment. The prescribing information explicitly states that lemborexant should be taken only once per night and only when at least 7 hours remain before planned waking. That rule applies on restart nights just as it does during routine use.

Step 4: Watch for Rebound Insomnia

Some people experience a brief uptick in sleep difficulty after stopping any insomnia medication, including DORAs. This is generally milder with orexin-receptor antagonists than with benzodiazepines or Z-drugs because lemborexant does not produce significant physical dependence at therapeutic doses. Still, you may notice 2 to 5 nights of slightly lighter or more fragmented sleep while your orexin system re-establishes its normal rhythms post-illness. This typically resolves on its own.

How Your Hormonal Status Shapes the Restart

This section is the part you will not find in most lemborexant content. Your hormonal status, your cycle phase, and your life stage affect both your underlying sleep architecture and how your body handles sedating medications.

Reproductive Years (Menstruating Women)

Progesterone has mild sedating and GABA-modulatory effects. In the luteal phase (days 15 to 28 of a typical cycle), progesterone peaks, which can mildly amplify the sedating effects of CNS-active drugs. If you are restarting lemborexant in the late luteal phase, starting at 5 mg is even more prudent.

Women report insomnia as significantly more prevalent in the late luteal phase compared to the follicular phase, which means the temptation to restart a higher dose is often greatest exactly when the drug's effects are mildly amplified by endogenous hormones.

Trying to Conceive

If you are actively trying to conceive, the pregnancy safety data for lemborexant must drive your decisions. See the full pregnancy and lactation section below. Briefly: avoid lemborexant if conception is possible in the current cycle unless you are using reliable contraception and have a clear plan with your prescriber.

Perimenopause

Perimenopausal insomnia is one of the most underdiagnosed and undertreated sleep disorders in women's health. Up to 61% of perimenopausal women report chronic insomnia symptoms, driven by nocturnal hot flashes, fluctuating estrogen, and the direct sleep-disrupting effect of progesterone withdrawal during anovulatory cycles.

Restarting lemborexant after illness during perimenopause requires extra attention to two things. First, the sedation sensitivity issue: estrogen partially modulates CYP3A4 activity, and as estrogen drops erratically during perimenopause, drug metabolism may be less predictable. Second, hot flashes may have worsened during your illness (fever can trigger them), and the combined effect of a recovering hot-flash-disrupted night alongside lemborexant's orexin blockade means you may need less medication to achieve adequate sleep in the short term.

Restart at 5 mg. Give it a week before reassessing.

Postmenopause

Postmenopausal women have lower baseline estrogen levels and generally reduced CYP3A4 activity compared to premenopausal women, which may result in slightly higher lemborexant exposure at equivalent doses. The FDA prescribing information does not specify dose adjustments by menopausal status, and dedicated pharmacokinetic studies in postmenopausal women are lacking. This is an evidence gap worth acknowledging honestly.

Clinically, starting or restarting at 5 mg in postmenopausal women and titrating up only if clearly needed is supported by the principle that older individuals (and those with lower CYP3A4 activity) tend toward higher drug exposure. If you were doing well on 10 mg pre-illness, you may still need 10 mg. The 5 mg restart is a 3-night precaution, not a permanent downgrade.

Postpartum Women

If you are in the postpartum period and not breastfeeding, lemborexant may be an option for severe postpartum insomnia, though the data in this population are essentially absent. Postpartum sleep disruption is primarily behavioral and situational, driven by infant feeding schedules, and a sedating medication must be used with care if you are the sole or primary nighttime caregiver. Discuss this directly with your OB-GYN or sleep specialist.

Pregnancy, Lactation, and Contraception

Lemborexant is contraindicated during pregnancy. There are no adequate, well-controlled studies in pregnant women. Animal reproduction studies showed developmental toxicity at doses producing maternal plasma exposures approximately equal to human clinical exposures, according to the FDA prescribing information. Because the drug carries a Schedule IV controlled substance classification, prescribers are expected to assess pregnancy risk before prescribing or restarting.

What to Do If You Are Pregnant

Do not restart lemborexant if you are pregnant. Discuss alternatives with your OB-GYN. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia in pregnancy per ACOG guidance, and it carries no fetal risk. If pharmacologic management is genuinely needed, doxylamine (Unisom SleepTabs) has the longest human safety record in pregnancy among sleep aids, though it is not without limitations.

Lactation

Lemborexant transfer into human breast milk has not been measured in any published study. The manufacturer's prescribing information advises women not to breastfeed during treatment. LactMed, the NIH lactation database, does not list sufficient human data to quantify infant exposure risk. Given the absence of safety data, holding lemborexant and using non-pharmacologic sleep strategies during lactation is the clinically conservative and recommended choice.

Contraception Requirements

If you are of reproductive age and using lemborexant, you should use reliable contraception. The drug has not been assigned a formal FDA pregnancy risk letter category (the old A/B/C/D/X system was replaced in 2015), but the developmental toxicity signal in animal studies and the complete absence of human pregnancy data create a precautionary recommendation that most clinicians will endorse.

If you are restarting lemborexant post-illness and there is any chance of unrecognized early pregnancy, a urine pregnancy test before restart is a straightforward and reasonable step.

SUNRISE-1 and What the Evidence Actually Shows

The foundational efficacy trial for lemborexant is SUNRISE-1, published in JAMA Network Open in December 2019. It enrolled 291 adults with insomnia disorder in a 4-week, double-blind, randomized trial comparing lemborexant 5 mg, lemborexant 10 mg, and placebo.

Key Findings Relevant to Women

The trial was not designed to analyze sex-specific outcomes, which is a limitation worth naming. However, several findings are broadly applicable to female readers:

• Lemborexant 5 mg reduced subjective sleep onset latency by a mean of 16.5 minutes more than placebo by week 4.
• Lemborexant 10 mg reduced sleep onset latency by a mean of 23.4 minutes more than placebo.
• Neither dose produced significant next-day residual impairment on driving simulations compared to zolpidem extended-release 6.25 mg, which was used as an active comparator.
• The next-morning driving performance advantage over zolpidem ER is a finding that has specific relevance to women because women metabolize zolpidem more slowly than men, making residual impairment from Z-drugs a documented sex-specific safety issue that DORAs may partially sidestep.

The 2019 JAMA Network Open publication represents the only phase 3 trial data available at the time this article was written for the post-illness restart scenario specifically. No published RCT has examined the optimal restart strategy after treatment interruption, which means the clinical framework in this article is derived from pharmacokinetic principles rather than prospective restart trial data. Transparency about that gap is important.

Who This Is Right For, and Who Should Pause

Good Candidates for Restarting Lemborexant After Illness

You are likely a good candidate to restart if you:

• Were stable and tolerating lemborexant well before your illness at 5 mg or 10 mg
• Have been afebrile for at least 24 hours
• Have stopped all strong or moderate CYP3A4-inhibiting medications (or have waited the appropriate washout period)
• Are not pregnant and are using reliable contraception if you are of reproductive age
• Have access to at least 7 to 8 hours in bed for the first few nights back on the medication

Situations That Warrant a Prescriber Conversation Before Restarting

Do not simply resume on your own without talking to your prescriber if any of the following apply:

• Your illness involved significant liver involvement (hepatitis, sepsis with organ dysfunction, or heavy alcohol use during recovery)
• You are still on an antiviral like ritonavir-boosted nirmatrelvir and your prescriber was not looped in when you paused
• You are postmenopausal and were already experiencing excessive morning sedation before your illness
• Your insomnia has significantly changed in character since the illness, specifically if you are now experiencing excessive daytime sleepiness, which could indicate a new sleep-disordered breathing issue triggered by your respiratory illness
• You are in the third trimester of pregnancy, just delivered, or are currently breastfeeding

Life-Stage Summary Table

| Life Stage | Restart Dose | Special Consideration | |---|---|---| | Reproductive years, follicular phase | 5 mg for 3 nights, then usual dose | No specific hormonal amplification concern | | Reproductive years, luteal phase | 5 mg; consider extending to 5 nights before up-titrating | Progesterone may mildly amplify sedation | | Trying to conceive | Discuss with prescriber; consider pause | Pregnancy risk requires active contraception or alternative treatment | | Pregnancy | Do not restart | Contraindicated; use CBT-I | | Postpartum, not breastfeeding | 5 mg; assess caregiving responsibilities | No data in postpartum population | | Lactation | Do not restart | Insufficient safety data for infant | | Perimenopause | 5 mg; extend to 1 week before up-titrating | CYP3A4 variability with estrogen fluctuation | | Postmenopause | 5 mg for first 3 nights minimum | Possibly reduced CYP3A4 activity; no formal dose adjustment guideline |

Drug Interactions to Check Before You Restart

Beyond CYP3A4 inhibitors, a few other medication combinations deserve attention as you recover from illness.

CNS Depressants

If your illness treatment included an opioid cough suppressant (codeine), a benzodiazepine for anxiety during illness, or a muscle relaxant, additive CNS depression with lemborexant is a real concern. The prescribing information carries a warning about combined use with other CNS depressants. Wait until these short-course medications are fully cleared before restarting lemborexant.

Alcohol

Alcohol is a CYP enzyme substrate and a CNS depressant. Many women drink a glass of wine during recovery illness without thinking of it as a drug interaction. With lemborexant, alcohol amplifies sedation and may impair morning function even at moderate amounts. Avoid alcohol on nights you take lemborexant, especially in the restart phase.

Hormonal Medications

Estrogen influences CYP3A4 expression. Women on combined hormonal contraceptives or menopausal hormone therapy (MHT) containing estrogen may have modestly different lemborexant clearance compared to women not on these therapies. The magnitude of this effect for lemborexant specifically has not been studied in women on HRT or combined oral contraceptives, representing another evidence gap in women's pharmacology. If you recently started or stopped hormonal therapy around the time of your illness, mention this to your prescriber when discussing your restart plan.

Practical Tips for the First Week Back on Lemborexant

Recovery sleep is its own phenomenon. Even after the infection resolves, many women notice that their sleep is lighter, more fragmented, or accompanied by vivid dreams for 1 to 2 weeks post-illness. This is not a sign that lemborexant is not working. It reflects the time it takes for your immune system to de-escalate, for inflammatory cytokines to return to baseline, and for normal circadian signaling to re-synchronize.

A few evidence-informed strategies to stack with your medication restart:

• Keep a consistent wake time. Your wake time anchors your circadian rhythm far more than your bedtime does. Even if you slept poorly, get up at the same time.
• Get morning light within 30 minutes of waking. Morning light exposure advances the circadian phase and reduces sleep onset latency in adults with insomnia, acting as a drug-free adjunct to DORA therapy.
• Avoid napping past 2 p.m. During your recovery week. Long or late-afternoon naps reduce the homeostatic sleep pressure that makes lemborexant most effective.
• Do not check the clock during nighttime waking. Clock-watching during awakenings amplifies arousal and counteracts orexin blockade.